Included in the formulation
АТХ:C.08.C.X.01 Mibephradil
C.08.C.X Other selective blockers of calcium channels with a predominant effect on blood vessels
Pharmacodynamics:The calcium channel blocker, which has an elective vasodilator effect on the coronary arteries, reduces the afterload on the heart and blood pressure, which in turn helps to reduce the need for myocardium in oxygen with simultaneous increased oxygen delivery to the myocardium.
Pharmacokinetics:Absorbed quickly and completely. Reaches Cmax in plasma after 1-2 hours. Bioavailability after a single admission is 70%, bioavailability against the achieved equilibrium concentration is 90%, while the volume of distribution is 200 liters. Binding to plasma proteins up to 99%. Metabolized by hydrolysis of the ester side chain and oxidation by the cytochrome P450 system. Excreted with bile (75%) and urine (25%), while less than 3% is excreted unchanged in the urine. General information clearance at oral chronic intake of therapeutic doses - 9 l / h.
Indications:Arterial hypertension, staberculous angina.
IX.I10-I15.I10 Essential [primary] hypertension
IX.I10-I15.I15 Secondary Hypertension
IX.I20-I25.I20 Angina pectoris [angina pectoris]
XVIII.R00-R09.R07.2 Pain in the region of the heart
Contraindications:AV-blockade II and III degree, gore-feedingVariability, gage, andIndividual intolerance.
Carefully:Pronounced violations of the liver, andOral stenosis, xheart failure, bRadiocardia.
Pregnancy and lactation:The drug is contraindicated for use during pregnancy and during breastfeeding.
Dosing and Administration:The initial dose is 50 mg, if necessary, increase the dose to 100 mg. The drug is taken once a day.
Side effects:Swelling of the lower extremities, dizziness, general weakness, in rare cases, bradycardia and AV-conduction disorders, bradycardia.
Interaction:In patients with a low activity of the isoenzyme CYP2D6 with simultaneous use increases the likelihood of increased concentrations in blood plasma dextromethorphan, propafenone, digoxin, tricyclic antidepressants, cyclosporine, metoprolol and an increased risk of toxic effects.
With simultaneous application, an increase in the concentration of quinidine in the blood plasma is possible.
Special instructions:No data.